The size-distribution of liver glycogen was shown to be distinctly affected by the anti-inflammatory drugs salicylate and indomethacin. By measurement of the incorporation of radioactive glucose into glycogen, salicylate was shown to have a depressing effect on overall liver glycogen metabolism. These effects appear to arise from the stabilizing of the lysosome by the drugs. The incorporation, via liposomes, of purified anti-i1,4-a-glucosidase antibodies into the liver lysosomes causes a distinct decrease in 1,4-a-glucosidase activity and in the content of high-molecular-weight glycogen. These changes are increased by prolonged liposomal antibody treatment and suggest that a possible feedback control mechanism operates in the incorporation of glycogen into lysosomes. These experiments may be useful as a model of glycogen turnover and its failure in glycogenosis type II (Pompe's disease).
A series of recent papers (Liillman-Rauch, 198 lab, 1982) have described how glycogenosis type II (Pompe's disease) may be mimicked in rats by intraperitoneal injection of the 1,4-a-glucosidase inhibitor Acarbose (Bay g 5421; Schmidt et al., 1977; Puls et al., 1980; Padilla et al., 1981) . This pseudotetrasaccharide appears to enter the liver lysosomes by fluid-phase endocytosis followed by lysosomal fusion (Silverstein et al., 1977; Daems et al., 1969) . The effect of this inhibitor treatment was monitored by histochemistry and cytochemistry, and a mechanism of action was proposed (LiillmanRauch, 1982) .
It has previously been shown by independent methods that in the liver, and some other tissues, a portion of the cellular content of glycogen is associated with the lysosomes (Geddes & Stratton, 1977a; Knecht & Hernandez, 1978; Brown et al., 1978; Rybicka, 1981) . Further, this glycogen is distinguished from that in the cytosol, to various extents, by size, structure and incorporation of radioactive precursors of glycogen synthesis (Geddes & Stratton, 1977a,b; Geddes et al., 1977a,b; Chee et al., 1983) . In addition, lysosomes have been reported to have been stabilized by anti-inflammatory drugs, although contradictory results may be obtained because of the difficulties associated with the preparation of stable consistent lysosomal samples in vitro (Ignarro, 1971a,b) . The experiments reported below are an attempt, based on combining the above observations, to test whether glycogen could be used as a 'monitor' of cellular lysosomal activity in vivo.
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Later experiments, designed to test further the sensitivity of glycogen, were based on the fact that the enzyme involved in the intralysosomal breakdown of glycogen is 1,4-a-glucosidase (EC 3.2.1.3). The genetic lack of this enzyme results in Pompe's disease (glycogenosis type II) (Hers & de Barsy, 1973) . Therefore antibody to this enzyme was prepared, encapsulated in liposomes and injected into test animals in an attempt to disturb lysosomal carbohydrate metabolism specifically (Gregoriadis, 1974; Ryman, 1974; Roerdink et al., 1976) . Slight differences in the physical properties of glycogen from post-mortem glycogenosis type II liver have previously been reported (Iwamasa et al., 1979) , but must be ignored, like other reports based on post-mortem tissue (Edstrom, 1972) , because of the rapid non-uniform degradation of glycogen after death (Geddes & Rapson, 1973) .
Materials and methods
Glycogen was extracted from the liver of rabbits or rats as described previously (Geddes & Stratton, 1977a,b) . Fractions were prepared on sucrose density gradients and assayed by using an iodine/ iodide reaction (Geddes & Rapson, 1973) . The molecular size of the fractions was determined as described previously , and all calculations were performed on mini-computers. All results presented are averaged from three separate determinations, the average variation in the concentration scale being typically less than +2%.
Samples of sodium salicylate or indomethacin, in iso-osmotic saline (0.9% NaCI), were injected intraperitoneally into the rats (male white Wistar, 200-250g Differences in the glycogen yield (as percentage of the wet weight of liver) were random and not obviously related to any experimental procedure employed, e.g. injection of drugs.
Acid 1,4-a-glucosidase activity was assayed at pH 4.0 with 4-methylumbelliferyl 1-a-D-glucopyranoside (Koch-Light Laboratories, Colnbrook, Bucks., U.K.) as a substrate (den Tandt, 1972; Willcox & Rattray, 1979) .
The enzyme was purified from a homogenate of 14 adult rat livers by a dextran absorption method (Auricchio et al., 1968) , with an additional purification step involving adsorption on DEAE-cellulose (25 cm x 2.5 cm column; 5 mM-Tris/HCI buffer, pH 7.0, containing 2 mM-EDTA and 5 mM-2-mercaptoethanol). The enzyme was eluted by a linear salt gradient (0-250mM-NaCl) and was judged pure by sodium dodecyl sulphate/polyacrylamide-gel electrophoresis. Approx. 2mg of the purified enzyme was used to raise rabbit antiserum. The immunogen was dissolved in 0.75 ml of deionized water, thoroughly emulsified with 0.75 ml of Freund's complete adjuvant and divided into three equal portions. These were administered to the rabbit by multiple subcutaneous injection at intervals of 2 weeks. Blood samples (10-15ml) were then taken from marginal ear veins at subsequent successive 2-week intervals over the following 16 weeks. The antiserum inhibited enzymic activity, and gave a single precipitin line with the purified enzyme in double-diffusion analysis. An immune y-globulin fraction was prepared from the antiserum by (NH4)2S04 fractionation and DEAE-cellulose chromatography (Deutsch & Fahey, 1967 Liposomes prepared by this method are small multilamellar (Gregoriadis et al., 1971) and lie in size between the small unilammellar and large multilamellar liposomes produced under different conditions. Liposomes were fractionated by Sepharose 4B gel filtration, to remove any contaminating multilamellar liposomes etc., and found to contain about 5% of the globulin (measured by disruption of the liposomes by 0.1% Triton X-100 and comparison with starting material). The liposome suspension was then injected equally into the tail veins of four adult rats. The residual y-globulin was dialysed, freeze-dried and used to make a fresh liposome suspension weekly, which was then injected into the remaining animals. Animals were killed over successive weeks, and either their whole liver glycogen was extracted or the glycogen from the lysosome-enriched fraction (Geddes & Stratton, 1977a ).
Results Fig. 1 . shows the effect on the molecular-weight distribution of liver glycogen of treatment with the anti-inflammatory drugs salicylate and indomethacin. These drugs, which appear to stabilize the lysosomal membrane (Ignarro, 197 la, b) , decrease the amount of high-molecular-weight as compared with low-molecular-weight glycogen. This induced metabolic inhomogeneity in glycogen turnover mimics the effect, for example, of a starvation/ re-feeding cycle in normal rabbits (Geddes, 1971; Geddes & Stratton, 1977b) . It seems possible that the observed effect arises from drug stabilization of the lysosomal membrane and the consequent decreased ingestion, by whatever mechanism, of high-molecular-weight glycogen into the lysosome. This is consistent with the observation (Geddes & Stratton, 1977a) that it is this glycogen that is normally associated with liver lysosomes.
Further experiments with increased doses of salicylate had [14Clglucose administered simultaneously, since this has proved to be a sensitive measure of glycogen metabolism (Geddes & Stratton, 1977b) . The effect of the salicylate on the molecular-weight distribution of the glycogen paralleled that shown in Fig. 1 , but in addition caused severe disturbance to the incorporation of radioactive glucose into glycogen, as depicted in Fig. 2 . There was increased incorporation of radioactivity into all sizes of glycogen, but the effect was most marked again in the high-molecular-weight fractions (fraction 8 has M, approx. 400 x 106-500 x 106).
Salicylate clearly has an overall depressing effect on glycogen metabolism, but the effect is most marked on high-molecular-weight material. Increasing dosage increases the overall effect evenly. It seems likely therefore that the decreased removal of glycogen into the lysosome has a depressing effect on continued glycogen synthesis, presumably through the well-known cascade control system (Cohen, 1982) . Experiments on the incorporation of anti-1,4-a-glucosidase antibody into liver cells by means of a liposomal carrier were also attempted. It is generally accepted now that the liver cells take up relatively most of liposomal material injected into the bloodstream, although its distribution between the parenchymal and the Kupffer cells remains unclear (Scherphof et al., 1980) . We have con- firmed (Table 1 ) that 1,4-a-glucosidase activity is decreased on introduction of the liposome-entrapped specific antibody, and have also shown that the absolute amount of high-molecular-weight glycogen associated with the lysosome-enriched fraction (Geddes & Stratton, 1977a) increases correspondingly (Table 1) . However, in whole glycogen, as shown in Fig. 3 , there is a greater increase in the low-molecular-weight region, resulting in a decrease in the relative amount of high-molecular-weight glycogen as compared with its lower-molecularweight counterpart. The size of this relative increase is clearly indicated in Table 2 . These results show similarities to the effects induced by the administration of anti-inflammatory drugs, as shown in Fig. 1 Lysosomal glycogen was prepared as described by Geddes & Stratton (1977a) . For other experimental details see the text. Control glycogens were isolated from untreated livers, but otherwise were subjected to the same procedures as the experimental tissues. The decrease in 1,4-a-glucosidase activity was assayed as the relative decrease in the specific activity of the 1,4-a-glucosidase in experimental animals relative to control (untreated) animals, Vol. 212 
Discussion
Our results with antibodies to 1,4-a-glucosidase are complementary to those obtained by LiillmanRauch (198 la,b, 1982) with a synthetic 1,4-aglucosidase inhibitor. However, we believe that we have extended the significance of this experimental approach insofar as: (a) the latter administered an 1,4-a-glucosidase inhibitor of which only a minor part would have ended up in the liver cell and its lysosomal apparatus (after intravenous dosage in humans about 90% of the inhibitor is excreted in the urine within 24h; Puetter, 1980) , whereas our specific antibody, encapsulated in liposomes, was targeted for the liver lysosomal system (Gregoriadis, 1974; Ryman, 1974; Roerdink et al., 1976) . (Table 1) , and possibilities of serious artifactual metabolic disturbance can be ignored (injection of 'empty' liposomes had no significant effect on the amount of glycogen, its molecular-weight distribution or on enzymic activities); (b) our studies are concerned with the variation in the effects within the vast molecular size range of liver glycogen molecules, i.e. alterations to the well-known metabolic inhomogeneity of liver glycogen (Stetten et al., 1956; Geddes, 1971; Geddes & Stratton, 1977a,b) and not just with the gross overall glycogen content as viewed histochemically and cytochemically.
Further, these results provide at least a partial explanation for the apparent molecular ordering of the synthesis and degradation of glycogen in the liver (Devos & Hers, 1979 , 1980 in that the molecules synthesized last are degraded first, and vice versa.
Our results show categorically that disturbance of normal liver lysosomal function, whether by interference with the membrane (Ignarro, 1971a,b) (Figs. 1  and 2 ) or by specific enzymic inhibition (Fig. 3 and Tables 1 and 2 ) of a single lysosomal enzyme, causes acute disturbance to the overall cellular carbohydrate metabolism, not just to the lysosomal portion. It is clear that, despite the absolute increase in glycogen associated with the lysosome (Table 1) , the relative amount of this high-molecular-weight material actually decreases ( Table 2 ), indicating that synthesis is continuing but that there is a previously undescribed 'feedback' on the process by which high-molecular-weight glycogen is encapsulated in the lysosomes. Since the high-molecular-weight glycogen is built on a protein backbone (Krisman & Barengo, 1975; Geddes & Stratton, 1977b; Chee & Geddes, 1977; , and in fact may be distinguished from its low-molecular-weight counterpart by its high protein content (Chee & Geddes, 1977) , it would seem likely that the synthesis and packaging of the large glycogen particles into the lysosomes proceeds by a process similar to that used in the synthesis of glycoprotein (Palade, 1975; Lodish et al., 1980) . Our results show that disturbance of normal processing at a later stage of the pathway (illustrated by LullmanRauch, 1982, Fig. lOa ) results in the accumulation particularly of low-molecular-weight glycogen, which the normal phosphorolytic pathway, without external hormonal stimulus (Cohen, 1982) , fails to clear. It is also possible that the slow clearance of material that disturbs lysosomal metabolism, such as Acarbose (Liillman-Rauch, 1981a , may exacerbate this effect.
The fact that disturbance of the non-phosphorolytic pathway of glycogen degradation clearly affects the phosphorolytic degradation, even with the relatively small amounts of antibody used in these experiments, may help to explain the observation that in type II glycogenosis, where lysosomal glycogen storage is massive because of the genetic lack of 1,4-a-glucosidase (Hers & de Barsy, 1973) , normal cell function is impaired to such an extent that most patients die in early childhood (Huijing, 1973) .
The two experimental approaches used in these studies involve disturbance of lysosomal integrity and metabolic function respectively, and affect the glycogen fraction that has been previously shown to be characteristic of lysosomes (Geddes & Stratton, 1977a) . Thus it may be feasible to use the measurement of total glycogen distribution on a molecularweight basis as a convenient monitor of lysosomal behaviour in vivo.
